NTLX.V · 2026-07-15 12:31:00

NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

Toronto, Ontario – TheNewswire - July 15, 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover (“MHH”), Germany, for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS) in adults.

The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee, is now advancing towards the next stage at Hannover Medical School, one of the key clinical sites of the study. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in an innovative one dosage form designed to reduce tics and comorbid symptoms in adults with TS while minimizing side effects.

In addition to Hannover Medical School, the trial will be conducted at Yale Child Study Center in New Haven, Connecticut, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel.

Building on the positive safety and efficacy results from the Phase IIa study, which showed an average tic reduction of 21% across the entire participants sample, as measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score scale, the Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110. Patients aged 18-65 will be randomized to receive either SCI-110 or placebo, with the primary efficacy endpoint being the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to the baseline. Safety will be assessed through monitoring of adverse events.

Dr. Adi Zuloff-Shani, Chief Technology Officer of NeuroThera Labs, commented: “The initiation of the German site marks an important step forward in our global development program for SCI-110. Tourette Syndrome is an unmet medical need condition with limited treatment options, particularly in adults who experience persistent, severe, and debilitating symptoms. We believe SCI-110 has the potential to offer a novel, more effective and safer alternative. We are committed to advancing this promising therapy and delivering meaningful data to support its future approval.”

About NeuroThera Labs Inc.

NeuroThera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

For further information, please contact:

Michal Efraty

IR Manager

NeuroThera Labs Inc.

Telephone: +972-3-7617108

Email: [email protected]

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Notice on Forward-Looking Statements

This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release.

Forward-looking information in this news release includes, without limitation, statements regarding: the conduct, progress and expected timing of the Company's Phase IIb clinical trial of SCI-110 for the treatment of Tourette Syndrome; the anticipated participation of additional clinical trial sites, including the Yale Child Study Center and the Tel Aviv Sourasky Medical Center; patient enrollment and randomization; the evaluation of the efficacy, safety and tolerability of SCI-110; the potential of SCI-110 to offer a novel or safer alternative to existing treatments; the generation of data to support future regulatory approval; and the continued development and potential commercialization of SCI-110.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking information necessarily involves known and unknown risks and uncertainties, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking information. Such factors include, without limitation: the inherent risks and uncertainties associated with clinical development, including the risk that the Phase IIb trial may be delayed, suspended or terminated; the risk that additional clinical trial sites may not be initiated as anticipated or at all; risks related to patient recruitment, enrollment and retention; the risk that trial results may not demonstrate the efficacy, safety or tolerability of SCI-110 or may not support further development or regulatory approval; the Company's reliance on third parties, including clinical sites, investigators and contract research organizations, to conduct the trial; risks associated with obtaining and maintaining regulatory clearances and approvals in multiple jurisdictions; the evolving regulatory environment applicable to cannabinoid-based therapeutics; the Company's need for additional financing to fund its clinical development programs; competition from existing and emerging therapies; risks relating to the protection of intellectual property; and the other risks described in the Company's continuous disclosure documents filed on SEDAR+ (www.sedarplus.ca).

The Company does not undertake any obligation to update or revise any forward-looking information, except as required by applicable securities laws.

← Back to feed